TY  - JOUR
TI  - Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study
AB  - OBJECTIVE Regorafenib, a multikinase inhibitor, is an approved third-line therapy for advanced gastrointestinal stromal tumors (GISTs). However, its routine clinical application is difficult due to the associated ad- verse events (AEs) reported by patients in the 1 st month, which leads to early discontinuation. In this study, we presented our experiences in toxicities management and the effectiveness of regorafenib in our institutional cancer center. METHODS Twenty-two patients treated with regorafenib as a third-line therapy for advanced GISTs were retro- spectively evaluated who had progressive disease after imatinib and sunitinib treatments. All patients received a full dose of 160 mg/day of regorafenib. RESULTS The average age of the patients was 49 years (range: 25-61 years), with a male preponderance (63.6%). The average follow-up time for the subjects was 114.2 months (16.2-210.3), while the median time of regorafenib using time was 7.7 months (1.9-29.1). The median overall survival (OS) of the patients was found as 10 months, while the 1-year OS rate was 38.3%. The median progression-free survival was found as 7.1 months. Regorafenib-related partial response was observed in 5 patients (22.7%), stable disease in 9 (40.9%), and progressive disease in 8 (36.4%). The disease control rate was 63.7%. Treat- ment-related grade 3/4 AEs were seen in ten (45.4%) patients. The most common AE was hand-foot skin reaction (5; 18.2%), followed by fatigue (3; 13.6%) and hypertension (2; 9.1%). Dose reductions were required in 7 patients (31.8%). The treatment was discontinued in a patient due to stroke. CONCLUSION Our results demonstrate promising activity and manageable side effects of regorafenib as third-line ther- apy of GIST in daily clinical practice in the Turkish population.
AU  - Ferhatoglu, Ferhat
AU  - Dogan, Izzet
AU  - KHANMAMMADOV, NİJAT
AU  - karabulut, senem
AU  - Bozbey, Hamza Ugur
AU  - Paksoy, Nail
AU  - TASTEKIN, DIDEM
DO  - 10.5505/tjo.2022.3756
PY  - 2022
JO  - Türk Onkoloji Dergisi
VL  - 37
IS  - 4
SN  - 1300-7467
SP  - 478
EP  - 483
DB  - TRDizin
UR  - http://search/yayin/detay/1175745
ER  -